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Abstract
Background: Despite advances in early diagnosis and treatment of cancer patients, metastasis remains the major
cause of mortality. TP53 is one of the most frequently mutated genes in human cancer, and these alterations can occur
during the early stages of oncogenesis or as later events as tumors progress to more aggressive forms. Previous studies
have suggested that p53 plays a role in cellular pathways that govern metastasis. To investigate how p53 deficiency
contributes to late-stage tumor growth and metastasis, we developed paired isogenic patient-derived xenograft (PDX)
models of triple-negative breast cancer (TNBC) differing only in p53 status for longitudinal analysis.
Methods: Patient-derived isogenic human tumor lines differing only in p53 status were implanted into mouse mammary
glands. Tumor growth and metastasis were monitored with bioluminescence imaging, and circulating tumor cells (CTCs)
were quantified by flow cytometry. RNA-Seq was performed on p53-deficient and p53 wild-type tumors, and functional
validation of a lead candidate gene was performed in vivo.
Results: Isogenic p53 wild-type and p53-deficient tumors metastasized out of mammary glands and colonized
distant sites with similar frequency. However, p53-deficient tumors metastasized earlier than p53 wild-type
tumors and grew faster in both primary and metastatic sites as a result of increased proliferation and decreased
apoptosis. In addition, greater numbers of CTCs were detected in the blood of mice engrafted with p53-deficient
tumors. However, when normalized to tumor mass, the number of CTCs isolated from mice bearing parental and
p53-deficient tumors was not significantly different. Gene expression profiling followed by functional validation
identified B cell translocation gene 2 (BTG2), a downstream effector of p53, as a negative regulator of tumor
growth both at primary and metastatic sites. BTG2 expression status correlated with survival of TNBC patients.
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Conclusions: Using paired isogenic PDX-derived metastatic TNBC cells, loss of p53 promoted tumor growth and
consequently increased tumor cell shedding into the blood, thus enhancing metastasis. Loss of BTG2 expression in
p53-deficient tumors contributed to this metastatic potential by enhancing tumor growth in primary and metastatic
sites. Furthermore, clinical data support conclusions generated from PDX models and indicate that BTG2 expression
is a candidate prognostic biomarker for TNBC.
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Background
Metastases are responsible for the majority of deaths
due to breast cancer. Metastasis is a multistage process
that occurs through a sequence of steps involving dis-
sociation of cells from the primary tumor, local invasion
and migration through the basement membrane and into
the circulation, extravasation into foreign organs, and fi-
nally tumor growth at distant sites [1]. Triple-negative
(negative for estrogen receptor, progesterone receptor, and
human epithelial receptor 2 (HER2) gene amplification)
breast cancer (TNBC) is an aggressively metastatic sub-
type with a disproportionately high rate of TP53 mutation
compared to other breast cancer subtypes.
The tumor suppressor protein p53 is lost or mutated
in about half of all human cancers, and in tumors where
this gene (TP53) is wild-type (WT), mechanisms fre-
quently exist to inactivate the protein. The majority of
TP53 mutations in basal-like breast cancer, an intrinsic
breast cancer subtype that largely overlaps with TNBC,
are insertions and deletions that result in TP53 truncation
and loss of function [2]. p53 loss disrupts pathways that in-
hibit metastasis and activates pathways that promote me-
tastasis. The pathways that are altered by p53 loss regulate
multiple stages of the metastatic cascade, including the
acquisition of stem cell-like properties, interactions with
the extracellular matrix, adhesion and migration [3, 4]. In
addition, p53 loss disrupts cell cycle checkpoints and
protects incipient tumor cells from undergoing apoptosis
or entering senescence, which in turn, creates opportun-
ities for tumor evolution and metastatic progression [5–7].
Furthermore, some TP53 mutants confer additional func-
tions that promote metastasis [8, 9]. Thus, the metastatic
potential of tumors can be enhanced by loss of p53 or by
expression of gain-of-function p53 mutants. However,
studies conducted in vivo indicate that p53 loss alone is in-
sufficient for metastasis [4, 8–10]. Interestingly, a genomic
study of treatment-naïve TNBC revealed that p53 loss or
acquisition of somatic mutations does not always emerge
as a founding event [11], suggesting that disruption of p53
function also can influence late stages of tumor develop-
ment. The presence of gain-of-function and loss-of-
function mutations in breast cancer warrants a thorough
characterization of these mutations in tumor progression.
In this study, we specifically studied the contribution made
by p53 deficiency to metastasis in late-stage triple-negative
breast cancer.
Most of the existing preclinical breast cancer xenograft
models used to study metastasis to lung or bone involve
injecting human cancer cell lines that have been exten-
sively cultured ex vivo into the tail vein or left ventricular
chamber of the heart, respectively. These methodologies
bypass all early steps in the metastatic cascade, including
escape from the primary site and survival in circulation.
By contrast, orthotopic patient-derived xenograft (PDX)
models of breast cancer are derived by engrafting tu-
mors obtained directly from patients into the mammary
fat pads of immune-compromised mice. Human breast
tumors have been shown to metastasize to physiologic-
ally relevant organs in these models, and as such,
orthotopic PDX models enable all stages of the meta-
static cascade to be studied within a more advanced
biological context in vivo [12–15].
We engineered paired isogenic PDX lines differing
only in p53 status to develop a breast cancer metastasis
model of TNBC that enabled longitudinal studies in
mice [16]. By studying the effect of p53 loss in an
already-metastatic PDX line, we investigated whether
p53 loss impacted late stages of tumor progression by
examining various stages of the metastatic cascade over
time. The contributions made by p53 silencing to breast
tumor growth, escape from the mammary gland, homing
and colonization of distant organs, and tumor growth
at metastatic sites were investigated. In addition, gene
expression profiling was conducted to identify p53
effectors that regulate metastasis.
Methods
Study approval
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals from the National Institutes of Health
(NIH) Institutional Animal Care and Use Committee
(IACUC). The protocol was approved by the Committee
on the Ethics of Animal Experiments of Washington Uni-
versity and the IACUC at MD Anderson Cancer Center.
Mice were euthanized when they became moribund and
when they reached defined study end points. Animals
were euthanized as dictated by the Association for
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Assessment and Accreditation of Laboratory Animal Care
International and IACUC euthanasia end points.
Establishment of PDX models of TNBC
PDX models were established according to published
protocols [17]. Briefly, 2.5 × 105 immortalized human
mammary stromal fibroblasts, derived from a patient who
underwent a reduction mammoplasty, were irradiated
(400 Rads) and mixed with 2.5 × 105 nonirradiated cells.
Fibroblasts were then mixed with 1 × 106 tumor cells
stably expressing click beetle red luciferase (CBR-luc)/
mCherry and 1/3 volume Matrigel. This mixture was
injected into the fourth mammary fat pads of 3- to 4-
week-old nonobese diabetic/severe combined im-
munodeficiency (NOD/SCID) mice (ordered from the
National Cancer Institute). For metastasis studies, p53-
deficient tumors were resected before they reached 1 cm
in diameter (approximately 9 weeks post-engraftment) to
enable time for metastasis to occur before mammary
tumor burden reached the maximum allowable size. For
studies monitoring mammary tumor growth, tumors were
not resected and mice were euthanized when tumors
reached 2 cm in diameter.
Bioluminescence imaging
Bioluminescence imaging (BLI) was performed in vivo as
previously described [18]. Briefly, after injection of
150 μg/g D-luciferin (Biosynth, Staad, Switzerland) in
phosphate-buffered saline (PBS), intraperitoneal (i.p.),
isoflurane-anesthetized mice were imaged with a charge-
coupled device camera-based BLI system (IVIS Lumina and
IVIS Spectrum; PerkinElmer, Waltham, MA, USA). Signals
were displayed as photons/s/cm2/sr. Regions of interest
were defined manually using Living Image Software, and
data were expressed as total photon flux (photons/second).
The first images were taken 2–3 weeks after tumor
implantation (PDX models), or immediately after tail vein
injection of labeled cells, and weekly thereafter. To assess
the appearance of metastases in the axillary lymph node,
mammary tumors were covered to block signal from the
primary site and allow visualization of metastases. To
quantify organ distribution, D-luciferin was adminis-
tered to live animals, and tissues were assessed with
BLI ex vivo at necropsy.
Quantification of metastatic frequency and manual
counting of metastatic foci
Mice were euthanized a minimum of 19 weeks post-
engraftment, and organs were subjected to BLI ex vivo. Or-
gans exhibiting regions of bioluminescence with Gaussian
distribution were counted as one nodule.
Blood processing for circulating tumor cell (CTC) analysis
Blood was extracted by cardiac puncture in the presence
of heparin. Whole blood was immediately transferred to
red blood cell (RBC) lysis buffer (Sigma-Aldrich, St.
Louis, MO, USA; R7757), inverted 10 times, and placed
on ice. Samples were centrifuged at 1500 rpm for 6 min,
RBC lysis buffer was carefully removed, and an add-
itional 7.5 ml of RBC lysis buffer was added. Samples
were again centrifuged at 1500 rpm for 6 min. Pellets
were resuspended in 350 μl of PBS with 0.5 % bovine
serum albumin (BSA) and assessed immediately by flow
cytometry. Whole blood from non-tumor-bearing mice
was processed alongside tumor-bearing mice as negative
controls. Whole blood from non-tumor-bearing mice
was spiked with 20,000 BC3-p53 knockdown (KD)
cultured cells as a positive control.
Flow cytometry for circulating tumor cells
For CTC studies, samples were analyzed on an Influx
cell sorter (BD, Franklin Lakes, NJ, USA). The entire
sample was flowed regardless of total cell number. Dead
cells were gated out by SyTox Blue staining and forward/
side scatter. Gates were set such that no cells appeared in
the mCherry + gate in negative controls. CTCs were iden-
tified as cells positive for mCherry fluorescence.
Cell culture and lentiviral transduction of Washington
University Breast Cancer line 3 (WU-BC3) cells
BC3-p53WT and BC3-p53KD cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10 % fetal bovine serum (FBS) and 1 %
penicillin-streptomycin. Cells were cultured at 37 °C, 5 %
CO2, and 5 % O2 in humidified air. When logarithmically
growing cells reached approximately 50 % confluency,
they were transduced with lentivirus encoding CBR-luc
and mCherry (FUW-CBR-luc-mCherry) in the presence
of 1 μg/ml polybrene. Cells were selected and subse-
quently grown in the presence of puromycin. Lentivirus
encoding BTG2 was produced by transfecting 293 T cells
with the target plasmid along with the packaging vectors
pDELTA8.9 and VSVG. Virus was removed from cells and
passed through a 40 μm filter 72 h after transfection. To
express BTG2 in BC3-p53KD, cells were transduced with
pHAGE-BTG2 or control lentivirus (pHAGE-GFP-eGFP).
Cells were transduced at a multiplicity of infection (MOI)
of 1 in the presence of 10 μg/ml polybrene. Flow cy-
tometry was used to isolate green fluorescent protein
(GFP)-positive cells. Expression of BTG2 was assessed
by quantitative polymerase chain reaction (qPCR).
Ribonucleic acid-sequencing (RNA-Seq) experiments and
data analysis
Tumors were harvested when they reached 0.5 cm and
were immediately snap frozen in liquid nitrogen to
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preserve RNA integrity and to avoid experimental ma-
nipulation that could lead to alterations in gene expres-
sion. Tumors were stored at -80 °C, thawed on ice in
Trizol, and homogenized with a pedestal homogenizer.
Total RNA was extracted with chloroform followed by
purification using the RNEASY kit (Qiagen, Venlo, The
Netherlands; 74104). Total RNA was treated with DNase
(TURBO DNase, Life Technologies, Carlsbad, CA, USA;
AM2238) followed by column purification (RNA
Clean & Concentrator-5, Zymo Research, Irvine, CA,
USA; R1015). mRNA was isolated by poly-A selection.
RNA Integrity Number (RIN) was assessed on a Bioanaly-
zer (Agilent Technologies, Santa Clara, CA, USA), and
only samples with RIN ≥ 8 were sequenced. RNA-Seq
libraries were prepared and sequencing was performed by
the Genome Technology Access Center (Washington
University, St. Louis, MO, USA). The RNA-Seq reads were
first mapped to the mouse (NCBI Build 37.2)
(GRCm37UCSC mm9) reference genome using Tophat2,
allowing a maximum of two mismatches per 75 bp
read end. The unmapped reads were then aligned to
the human genome (NCBI Build 37.2) (GRCh37/
UCSC hg19) using the same tool and parameters. Par-
tek Genomics Suite v6.6 and its genomic feature data-
base (RefSeq Transcripts - 2014-01-03) were used to
quantify the gene-level read counts. The differential
analyses for gene/isoform expression were performed
using DESeq2. The log2 fold change 1.5 and p value
cutoff <0.05 were used to identify differentially
expressed genes. Pathway analysis was performed
using the GeneGo application of the MetaCore pro-
gram (Thomson Reuters, New York, NY, USA).
Real-time polymerase chain reaction (RT-PCR)
Total RNA was isolated by Trizol-chloroform extraction
followed by purification using the RNEASY kit as de-
scribed above. RNA was DNase-treated as described
above. RIN was assessed as described above, and only
samples with RIN ≥8 were used for qPCR analyses. A
dynamic range test (standard curve) was performed
using reverse transcription (RT) conditions to determine
the range of RNA to be used in all subsequent reactions.
Each 40 μl RT reaction consisted of no more than 4 μg
template RNA. RNA was diluted 1:10 and reverse tran-
scribed using the Superscript III system (Invitrogen,
Carlsbad, CA, USA). The resulting cDNA was used for
qPCR using the TaqMan Gene Expression Assays (Applied
Biosystems, Foster City, CA, USA), and data were normal-
ized to a multiplexed endogenous control, GAPDH. No-
template and no-RT controls were run on each plate, and
amplification was not observed for any samples. qPCR
was performed on the ViiA 7 Real-Time PCR System (Life
Technologies).
Immunohistochemistry (IHC)
Mammary tumors were fixed in 10 % neutral buffered
formalin for 24–48 h. Samples were then washed three
times with PBS and transferred to 70 % ethanol, then
embedded in paraffin. Five micron sections were cut and
baked at 65 °C for 60 min. Sections were deparaffinized
by immersing in xylene (Thermo Fisher Scientific,
Waltham, MA, USA) three times for 5 min each and
rehydrated by immersing twice through a decreasing
gradient of alcohol (100 %, 95 %, 70 %, 50 %, and
distilled H20) for 2 min each. Antigen retrieval was
carried out by boiling samples in rodent decloaker
agent (Biocare Medical, Concord, CA, USA; RD913M)
for 30 min followed by cooling at room temperature
for an additional 15 min. Endogenous peroxidase
activity was blocked by incubating sections in Perox-
idase Blocking Reagent (Dako, Glostrup, Denmark)
for 15 min at room temperature. Nonspecific interac-
tions were blocked by incubating sections in Protein
Block (Dako) for 1 h at 4 °C. Primary and secondary
antibodies were diluted in Antibody Diluent (Dako).
Antibodies were diluted as follows: cytokeratin 18
(CK-18) (Abcam, Cambridge, UK; Ab82254), 1:200;
phospho-histone H3 (pHH3) (Sigma-Aldrich; H9908),
1:1500; cleaved caspase 3 (CC3) (Cell Signaling Tech-
nology, Danvers, MA, USA; 9661), 1:200. For CC3,
the ImmPRESS Reagent Anti-Rabbit IgG kit was used
(Vector Laboratories, Burlingame, CA, USA; MP-
7401). For pHH3, the ImmPRESS Reagent Anti-Rat
IgG kit was used (Vector Laboratories MP-7404). For CK-
18, the ImmPRESS M.O.M kit (Vector Laboratories;
MP-2400) was used.
Statistics
To normalize the photon flux values to the time of study
end point, the photon flux and the logarithm of the
photon flux in each organ were plotted versus time to eu-
thanasia. Plots of the photon flux showed that most values
increased approximately exponentially over time, and
plots of the logarithm of the photon flux indicated that
most values were fitted by a straight line [19, 20]. We
therefore assumed that the photon flux increased expo-
nentially over time. Thus, the normalized photon flux was
obtained by dividing the photon flux measured in each by
the exponential value of its time to euthanasia. Since the
sample sizes in most groups were relatively small,
Wilcoxon rank sum test was used to evaluate the mean
differences in the photon flux values in each organ, time
to euthanasia, and time to lymph node metastasis between
the groups of mice. F-test was used to account for the
time effect in the analysis of variance (ANOVA) model to
assess whether p53 silencing was significantly correlated
with the log2-transformed CTC counts. Statistical analyses
were performed using R (http://www.r-project.org/).
Powell et al. Breast Cancer Research  (2016) 18:13 Page 4 of 16
Survival analysis
The univariate Cox proportional hazard model was used
to assess the correlation of gene expression with patient
overall survival and metastasis-free survival (Table S3 in
Additional file 1), and the likelihood ratio test p values
were reported. The dataset from The Cancer Genome
Atlas (TCGA) [21] was used for determining overall
survival of breast cancer patients and TNBC patients.
Datasets from the San Diego cohort [22], the NKI cohort
[23], and the Oxford cohort [24] were used for determin-
ing metastasis-free survival. Log-rank tests were used to
estimate the p values between high and low expression
groups (using top and bottom 25 % as the cutoff for
grouping).
Preparation of tumors for flow cytometery for stem
markers and mammosphere formation assays
For use in flow cytometry and mammosphere assays,
BC3-p53WT and BC3-p53KD tumor cells not expressing
CBR-luc-mCherry were implanted contralaterally into
the fourth mammary gland (n = 4 tumors BC3-p53WT,
n = 4 tumors BC3-p53KD). When tumors reached
0.5 cm in diameter, they were isolated from mammary
glands and dissociated into single cells and organoids in
collagenase and hylauronidase for 4 h at 37 °C on a rota-
tor. Tumor cells were washed in DMEM/F12 with 5 % bo-
vine calf serum, and red blood cells were lysed for 5 min
at room temperature (RBC lysis buffer; Sigma-Aldrich).
Cells were passed through a 100 μm, then 40 μm filter.
Mouse stromal cells were depleted using magnetic-
activated cell sorting (Miltenyi Biotec, Bergisch Gladbach,
Germany; MACS mouse cell depletion resin) according to
the manufacturer’s instructions. Effective depletion of
mouse cells was confirmed by staining with a mouse-anti-
H2kd (mouse-specific MHC class I H-2Kd haplotype)
antibody conjugated to PE/Cy7 (BioLegend, San Diego,
CA, USA clone SF1-1.1), followed by flow cytometry.
Flow cytometery
Following tumor digestion and mouse cell depletion,
cells were immediately placed in PBS + 0.5 % BSA and
stained with antibodies for flow cytometry for 20 min at
4 °C at a concentration of 5 million cells/mL. Antibodies
used were: rat anti-CD44 conjugated to allophycocyanin
(APC) (BD Pharmingen San Jose, CA, USA; clone IM7),
mouse anti-CD24 conjugated to fluorescein isothiocyan-
ate (FITC) (BD Pharmingen clone ML5), mouse anti-
GD2 (unconjugated, BD Pharmingen clone 14.G2a),
goat-anti-mouse secondary antibody conjugated to APC
(BD Pharmingen). Cells were stained with Ghost Dye
Violet 510 (Tonbo Biosciences, San Diego, CA, USA) for
viability. After staining, cells were fixed in 1 % parafor-
maldehyde then analyzed by an LSRFortessa X-20 flow
cytometer (BD).
Mammosphere formation assays
Immediately following tumor digestion and mouse cell
depletion, cells were plated at a concentration of 1000
cells per well on an ultra-low-binding 96-well plate
(Corning, New York, NY, USA) in complete MammoCult
medium (STEMCELL Technologies, Vancouver, BC,
Canada), supplemented with 1 % methylcellulose to
immobilize cells. Mammospheres were manually counted
12 days after plating. Primary mammosphere formation
efficiency was calculated as percent of mammospheres
formed divided by total number of cells plated. Primary
mammospheres were collected, dissociated into single
cells using TrypLE Express (Life Technologies), and
replated in MammoCult containing 1 % methylcellulose
to form secondary mammospheres. Secondary mammo-
spheres were manually counted 12 days after plating.
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assays
Cells were seeded in 24-well plates (20,000 cells per
well) in complete cell culture media. Four consecutive
time points were harvested post-seeding (24, 48, 72 and
96 h). Every 24 h, plates were incubated with MTT
reagent (0.5 mg/ml) for 1 h at 37 degrees, 5 % CO2, and
5 % O2 in humidified air (normal cell culture condi-
tions). After incubation with MTT reagent, media was
removed from cells, and 500 μl DMSO was added per
well to solubilize purple formazan crystals. The plate
was then read on a Clariostar plate reader (BMG
Labtech, Cary, NC, USA) at 570 nm for formazan
absorbance and 690 nm for background absorbance, and
these values were normalized by subtraction. Each
condition was performed in triplicate.
Cell proliferation assays
Cells were seeded in 6-well plates (80,000 cells per well)
in complete cell culture media. Four consecutive time
points were harvested post-seeding (24, 48, 72 and 96 h).
Every 24 h, cells were trypsinized, resuspended to break
remaining cell clusters, loaded onto cell counting cham-
bers, and read on a CellOMeter (Nexcelom Bioscience,
Lawrence, MA, USA). Each condition was plated in
biological triplicates, and each well was counted in
duplicate. Each chamber was read in triplicate.
Western blotting
Samples were lysed in Mammalian Cell Lysis Buffer
(50 mM Tris, pH 8.0, 2 mM dithiothreitol (DTT),
5 mM ethylenediaminetetraacetic acid (EDTA), 0.5 %
NP-40, 100 mM NaCl) with added protease inhibitors
(1 μM mycrocystin, 2 mM phenylmethanesulfonyl
fluoride (PMSF), 1 × protease inhibitor cocktail (Sigma-
Aldrich; P8340-5ML), 1 × phosphatase inhibitor cock-
tail (Calbiochem, San Diego, CA, USA; 524625-1SET)),
Powell et al. Breast Cancer Research  (2016) 18:13 Page 5 of 16
and 10–30 μg total protein was loaded onto Bio-Rad
(Hercules, CA USA) Criterion gels and transferred to
nitrocellulose for Western blotting using standard
procedures. Antibodies used for Western blotting in-
cluded those recognizing BTG2 (sc-33775, Santa Cruz
Biotechnology Inc., Dallas, TX, USA), and α-tubulin
(2144, Cell Signaling Technologies). Protein was detected
using enhanced chemiluminesence (ECL) (34080, Thermo
Fisher Scientific) on a G-Box imager (Syngene, Frederick,
MD, USA).
Ethics, consent, and permission
All animal experiments were authorized by the IACUC
committee at MD Anderson. RNA-seq data analyzed in
this manuscript are publically available at (GEO Accession
number GSE76433). We confirm that this study did not
involve human patients and no consent was required.
Results
Modeling human breast cancer metastasis in mice
The original line (WU-BC3) was previously generated by
engrafting the primary breast tumor of a patient with
metastatic TNBC directly into the humanized mammary
fat pad of NOD/SCID mice [16]. This patient presented
with metastases to lung, bone, adrenal gland, and medi-
astinal lymph nodes. DNA sequencing revealed that this
tumor is wild-type (WT) for TP53 [25], and further-
more, p53 is known to be functional in these cells (both
p53 and p21 were induced in response to ionizing radi-
ation) [16]. Gene expression profiling and application of
the PAM50 subtype-based predictor categorized WU-
BC3 as nonbasal TNBC that clustered most closely with
the HER2-E subtype [26]. The HER2-E molecular sub-
type has been reported in approximately 9 % of TNBC
and approximately 30 % of HER2-E breast cancers are
WT for TP53 [21]. WU-BC3 cells were infected with
control retroviruses or retroviruses encoding p53-
specific short hairpin RNAs (shRNAs) [16] to generate
cells denoted BC3-p53WT and BC3-p53KD, respectively,
which were then further engineered to stably express
both bioluminescent (click beetle red luciferase, CBR-
luc) and fluorescent (mCherry) markers by lentiviral
transduction (Figure S1A in Additional file 2). Silencing
of p53 in WU-BC3 caused an increase in cellular prolif-
eration in vitro (Figure S1B and C in Additional file 2).
The morphology of the BC3 line was not detectably al-
tered (Figure S1D in Additional file 2). Transduced cells
were implanted into the humanized mammary fat pads
of NOD/SCID mice. Thus, isogenically matched PDX
lines differing only in p53 status were used throughout
our studies, enabling tumor growth and metastasis to be
monitored noninvasively and repetitively in living mice
and in organs isolated from these mice using biolumin-
escence imaging (BLI).
p53 deficiency results in increased tumor growth in
mammary glands
The paired BC3-p53WT and BC3-p53KD cells were
engrafted into mammary fat pads of individual NOD/
SCID mice and BLI was performed to follow tumor
growth and metastasis as a function of time (Fig. 1a).
BLI and caliper measurements revealed that p53-
deficient tumors grew faster than their p53 WT counter-
parts (Fig. 1b, c). Immunohistochemistry was used to de-
termine if the increased growth of p53-deficient tumors
in the mammary gland was due to greater proliferation
and/or less apoptosis. Five weeks after tumor implant-
ation, p53-deficient tumors exhibited a significant in-
crease in proliferating cells (Fig. 1d) and a significant
decrease in apoptotic cells (Fig. 1e). By 9 weeks post-
engraftment, proliferation and apoptosis were not
significantly different, which was consistent with the
observation that tumor growth rates equalized at later
time points (Fig. 1b,c). In addition to faster primary
tumor growth, metastasis to the axillary lymph node was
observed earlier in mice harboring p53-deficient tumors
(Fig. 1f ). This suggested that BC3-p53KD tumors
completed selected stages of the metastatic cascade
more efficiently than BC-p53WT tumors.
p53 deficiency leads to increased growth at metastatic sites
Tumor-bearing mice were monitored for signs of declin-
ing health and euthanized when they exhibited moribund
symptoms, typically at approximately 30 and approxi-
mately 20 weeks post-engraftment of BC3-p53WT and
BC3-p53KD tumors, respectively (Fig. 2a). At the time of
euthanasia, organs were isolated and subjected to BLI ex
vivo. Metastases were observed in lungs, livers, bones, and
brains of tumor-bearing mice (Fig. 2b). Immunohisto-
chemistry using a human-specific cytokeratin 18 (CK18)
antibody confirmed that primary and metastatic lesions
were of human origin (Fig. 2c). p53 silencing did not alter
the frequency of metastasis to various organs (Fig. 2d).
However, even though mice bearing BC3-p53KD tumors
were euthanized earlier than mice bearing BC3-p53WT
tumors (Fig. 2a), the photon flux measured in the lungs of
mice harboring p53-deficient tumors was higher than that
measured in the lungs of mice harboring p53WT tumors
at the study end points (Fig. 2e). Bioluminescence of
lungs, livers, bones, and brains was significantly greater in
mice bearing p53-deficient tumors, even when photon
flux was normalized to the date of euthanasia (Fig. 2f).
Normalization to photon flux of mammary tumors was
not possible because they were resected in a survival
surgery prior to the study end point. This suggested that
p53 silencing enhanced the metastatic capacity of the BC3
tumor line.
Limiting dilution cell transplantation assays were per-
formed to determine if the number of tumor-initiating
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cells increased upon p53 silencing. The results of this
assay demonstrated that the majority of both BC3-
p53WT and BC3-p53KD cells were capable of tumor ini-
tiation (Figure S2A, B in Additional file 3). Tumors were
also dissociated into single cell suspensions and assessed
for their ability to grow as nonadherent mammospheres, a
property of tumor-initiating cells [27]. The ability of BC3
tumor cells to initiate primary (Figure S2C in Additional
file 3) and secondary (Figure S2D in Additional file 3)
sphere formation was not significantly changed upon p53
silencing. Finally, p53 silencing did not significantly alter
the percentage of CD44high/CD24low cells [28] in the
tumor cell population (Figure S2E in Additional file 3).
Taken together, these data demonstrated that p53 silen-
cing did not significantly alter the stem-like properties of
these breast cancer cells.
Fig. 1 p53 silencing enhances breast tumor growth and metastasis in vivo. BC3-p53WT and BC3-p53KD cells expressing CBR-luc and mCherry
were implanted into the humanized mammary fat pads of NOD/SCID mice. Bioluminescence imaging (BLI) was performed to monitor tumor
growth and metastasis as a function of time. a Representative images showing growth and metastasis of BC3-p53WT and BC3-p53KD tumors.
Due to rapid tumor growth BC3-53KD tumors were resected at approximately 9 weeks post-engraftment. b Total photon flux from each mammary
tumor was quantified from BLI, and values were plotted as a function of time. c Tumors were measured with calipers, and values were plotted as a
function of time. n = 18, BC3-p53WT; n = 18, BC3-p53KD. p = 0.004, t test (b and c). d and e 5 weeks and 9 weeks post-engraftment, tumors were
harvested, formalin-fixed, sectioned, and stained with antibodies against phospho-histone H3 (pHH3) (d) and cleaved caspase 3 (CC3) (e). Positive
regions were counted manually, and percentage of positive cells was calculated from DAPI-stained nuclei. Each data point is the average of at least six
images from an individual mouse. Paired t tests, p = 0.01 for pHH3 at 5 weeks; p = 0.30 for pHH3 at 9 weeks; p = 0.04 for CC3 at 5 weeks; p = 0.20 for
CC3 at 9 weeks. f BLI was performed biweekly to detect the appearance of lymph node metastases. p = 0.001, Wilcoxon rank sum test. Each data point
represents one mouse. All error bars represent standard error of the mean (SEM)
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Fig. 2 p53 silencing increases bioluminescence in metastatic sites. BC3-p53WT and BC3-p53KD were implanted into mouse mammary fat pads.
Frequency and magnitude of metastasis were assessed with bioluminescence imaging (BLI). a Animals were euthanized when declining health
was observed. The time post tumor-engraftment to euthanasia of animals implanted with BC3-p53WT or BC3-p53KD was quantified. Each data
point represents one mouse. p = 0.002, Wilcoxon rank sum test. b Lungs, livers, long bones, and brains of mice implanted with BC3-p53WT or
BC3-p53KD were imaged with BLI ex vivo at necropsy. Representative images are shown. Scale applies to each image in the panel, and magnitude of
scale is indicated below each image. c Mammary tumors and lungs were harvested from mice implanted with BC3-p53KD. Tissues were sectioned and
stained with cytokeratin 18 (CK18) to assess regions of human epithelial tumor (positive) and surrounding mouse tissue (negative). Objectives used
were: 20 × composite (top panels), 10 × (middle panels), and 20 × (bottom panels). d Frequency of metastasis to the indicated organs was quantified
with ex vivo BLI 19–40 weeks post-engraftment. e Lungs were extracted, and total photon flux was assessed with BLI, quantified, and plotted vs. time
post-engraftment to study end point. p = 0.03, linear regression analysis of the slopes. f Lungs, livers, bones, and brains were extracted and assessed
with BLI. Total photon flux was quantified and normalized to time post tumor-engraftment to euthanasia. n = 21, p53WT; n = 14, p53KD. p <0.001
(lung); p = 0.001 (liver); p = 0.002 (bone); p = 0.01 (brain), Wilcoxon rank sum tests. Each data point represents one organ from one mouse. All error bars
represent standard error of the mean (SEM)
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To determine the effect of p53 silencing on the ability
of breast tumor cells to colonize and grow in distant
organs, cells were injected to the tail vein (for lung
metastases) or the left ventricular chamber of the heart
(for bone metastases). Bioluminescence was tracked in
vivo. Silencing of p53 resulted in faster tumor growth in
the bones (Figure S3A in Additional file 4) and lungs
(Figure S3B in Additional file 4) of injected mice. Thus,
p53 silencing promoted tumor growth in both primary
(mammary gland) and secondary (lung and bone) sites.
Circulating tumor cell (CTC) release correlates with tumor
growth
To assess the ability of tumor cells to enter into the
bloodstream, CTCs present in the blood of tumor-
bearing animals were quantified by flow cytometry at
various times following tumor engraftment. The number
of CTCs able to metastasize out of the mammary glands
of tumor-bearing mice increased as a function of time,
and greater numbers of CTCs were detected in mice
harboring BC3-p53KD tumors than those harboring
BC3-p53WT tumors at each time point examined
(Fig. 3a). CTCs were not detected in either line prior to
9 weeks post-implantation. The total number of CTCs
released over the 18-week period by mice harboring
BC3-p53KD tumors was significantly higher than the
total number released by mice harboring BC3-p53WT
tumors (Fig. 3b). However, when total CTC numbers
were normalized to photon flux (Fig. 3c, Figure S4A in
Additional file 5) or volume (Figure S4B in Additional
file 5) of the corresponding mammary tumor, the differ-
ence was not statistically significant. p53 status did not
influence CTC numbers (Fig. 3d) from mice bearing
equal-sized tumors (Fig. 3e), validating this normalization.
Similarly, CTC number correlated with intensity of
photon flux (Figure S4C in Additional file 5) and volume
(Figure S4D in Additional file 5) of mammary tumors
within each mouse. The number of CTCs also correlated
with photon flux in the lungs of tumor-bearing mice
(Figure S4E in Additional file 5), suggesting that our
method of CTC detection effectively measured CTCs that
would eventually seed metastatic lesions. The number of
spatially distinct metastatic lesions in the lungs of tumor-
bearing mice was not significantly altered when p53 was
silenced (Fig. 3f), suggesting that p53 deficiency did not
influence the ability of CTCs to colonize the lungs.
As expected, CTC number did not correlate with
time of detection of lymph node metastasis (Figure
S4F in Additional file 5). Taken together, these data
indicated that p53 silencing did not increase the abil-
ity of tumor cells to escape the mammary glands, to
home to the lung, or to colonize the lung. Rather, in-
creased tumor growth in primary and metastatic sites
was likely responsible for the observed increases in
tumor progression and metastasis upon p53 silencing.
p53 silencing alters expression of genes involved in tumor
progression
RNA-sequencing (RNA-Seq) was performed on BC3-
p53WT and BC3-p53KD mammary tumors to identify
genes with altered expression in response to p53 silen-
cing. Tumors were harvested when they reached ap-
proximately 0.5 cm in diameter. Using a bioinformatics
pipeline that distinguishes human epithelial tumor cell
transcripts from transcripts originating from the murine
host (see Methods), we identified 109 significantly up-
regulated genes and 51 significantly downregulated
genes in human tumor cells from BC3-p53KD tumors
(n = 3) relative to BC3-p53WT tumors (n = 4) (using a cut-
off value of p ≤0.05 and log2 fold change ≥1.5) (Table S1 in
Additional file 6). p53 silencing resulted in a 10.9-fold
reduction in TP53 expression in BC3-p53KD tumors rela-
tive to BC3-p53WT tumors. The top enriched processes
differentially affected by p53 silencing were those related to
interactions with the surrounding microenvironment, in-
cluding extracellular matrix (ECM) remodeling, connective
tissue degradation, cell-matrix interactions, cell adhesion,
epithelial to mesenchymal transitions (EMT) and apoptosis
(Table S2 in Additional file 7). Alterations in components
of these pathways are known to contribute to various
stages of metastasis [29, 30], including growth in primary
and metastatic sites [29, 30].
Gene expression profiling identifies p53-regulated genes
that are clinically significant
Changes in gene expression that accompany disruptions
in the p53 pathway are associated with poor prognosis
in breast cancer patients [31–37]. The gene expression
signature derived in this study was reviewed to create a
mini-signature of genes known to be in the p53 pathway.
The dataset from The Cancer Genome Atlas (TCGA) [21]
was then used to determine if the expression (or lack
thereof) of each gene in the mini-signature was predictive
of overall survival for breast cancer patients (n = 1022) as
well as for those patients with TNBC (n = 119). Datasets
from the San Diego cohort (n = 286) [22], the NKI cohort
(n = 295) [23] and the Oxford cohort (n = 210) [24] were
used to correlate gene expression with metastasis-free sur-
vival (Table S3 in Additional file 1). B cell translocation
gene 2 (BTG2) was chosen from the mini-gene signature
for validation and further analysis.
BTG2 regulates growth of primary and metastatic tumors
BTG2 is a direct transcriptional target of p53, and
quantitative RT-PCR (qPCR) validated that basal BTG2
expression was dependent on the p53 status of the origin-
ating cell lines (Fig. 4a) [38–40]. We then ectopically
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expressed BTG2 in BC3-p53KD cells, using GFP expres-
sion as a control (Figure S5A, B in Additional file 8).
Ectopic expression of BTG2 reduced the growth of BC3-
p53KD cells in vitro relative to control cells (Figure S5C,
D in Additional file 8). Reduced tumor growth was also
observed in the mammary glands of engrafted mice
Fig. 3 p53 silencing increases CTCs in the blood as a function of increased tumor growth. Mouse mammary fat pads were engrafted with BC3-p53WT
or BC3-p53KD. Whole blood was extracted from mice in a terminal blood draw by cardiac puncture. Red blood cells were lysed, and circulating tumor
cells (CTCs) were assessed by flow cytometry for mCherry-positive cells. Bioluminescence imaging (BLI) was performed on mammary tumors and lungs
at necropsy. a CTCs were quantified by flow cytometry at the indicated time points. p = 0.71 (5 weeks); p = 0.06 (9 weeks); p = 0.40 (12 weeks); p = 0.10
(15 weeks); p = 0.07 (18 weeks), Wilcoxon rank sum tests. b CTCs were quantified as in (a), and numbers from each time point were combined to
increase cohort size. p <0.001, F-test. c CTC number from each mouse was normalized to total photon flux of the corresponding primary tumor. Data
are presented as a combination of all time points as in (b). p = 0.072, F-test. d and e BC3-p53WT tumors were implanted to mammary glands 3 weeks
prior to implantation of BC3-p53KD, and CTCs were quantified on the same day by flow cytometry (d, p = 0.43, t test) when tumors were equivalent in
size (e, p = 0.73, t test). f Spatially distinct regions of bioluminescence in lungs of tumor-bearing mice were quantified manually. p = 0.09, Wilcoxon rank
sum test. Each data point represents one mouse. All error bars represent standard error of the mean (SEM)
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Fig. 4 BTG2 negatively regulates growth of BC3-p53KD tumors in primary and metastatic sites. BC3-p53WT or BC3-p53KD were implanted into
mouse mammary fat pads, and tumors were harvested when they reached 0.5 cm diameter. Ribonucleic acid (RNA) was extracted from tumors,
and gene expression changes were assessed with RNA-sequencing (RNA-Seq). a RNA from BC3-p53WT or BC3-p53KD tumors was reverse transcribed,
and quantitative real-time polymerase chain reaction (qRT-PCR) using a probe and primer set for B cell translocation gene 2 (BTG2) was performed.
p = 0.0001, t test. Each dot is a biological replicate representing one tumor from one mouse. b BTG2 or green fluorescent protein (GFP) (control) was
expressed in BC3-p53KD cells by lentiviral transduction, and cells were implanted to mouse mammary fat pads. Mice were subjected to
bioluminescence imaging (BLI) weekly, and total photon flux from mammary tumors was quantified at each time point. n = 5 mice (10 tumors) in each
group. p <0.001 for mammary tumors 6 weeks post-engraftment, Wilcoxon rank sum test. p <0.001 using linear mixed-effect model of tumor growth
over the time course. c BTG2 or GFP was expressed in BC3-p53KD as in (b), and cells were injected into mouse tail veins to model the final stages of
lung metastasis. Mice were subjected to BLI weekly, and total photon flux from lungs was quantified at each time point. n = 4 mice in each group.
p = 0.002, linear mixed effect model. d Total photon flux from lungs of mice in (c) was assessed with BLI ex vivo at necropsy and quantified. p = 0.001,
t test. Each data point represents one mouse, n = 4 mice per group. e Hematoxylin and eosin (H & E) staining of lungs of mice in (c) and (d). All error
bars represent standard error of the mean (SEM)
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(Fig. 4b) as well as in the lungs of mice after tail vein injec-
tion (Fig. 4c, d, e). Taken together, these results suggest that
BTG2 functions downstream of p53 to negatively regulate
growth of both primary and metastatic breast tumors.
Expression of BTG2 correlates with breast cancer patient
survival
To explore the prognostic relevance of BTG2 expression,
survival analyses were performed. Low BTG2 expression
correlated with decreased overall survival (Fig. 5a, Table
S3 in Additional file 1) and metastasis-free survival
(Fig. 5b) of breast cancer patients, indicating that BTG2 is
a clinically relevant suppressor of breast tumor progres-
sion. In addition, low BTG2 expression correlated with
decreased overall survival of patients with TNBC (Fig. 5c,
Table S3 in Additional file 1). Thus, in addition to its
predictive value in other subtypes of breast cancer, BTG2
expression may be a prognostic marker for TNBC.
Discussion
Using a paired set of PDX models of TNBC differing
only in p53 status that metastasize to similar organs as
those observed in breast cancer patients, we demon-
strated that p53 silencing enhanced tumor growth in
both primary and metastatic sites. The BC3 lines used in
this study were generated from a patient with metastatic
breast cancer whose tumor was wild-type for p53. Thus,
expression of wild-type p53 alone was insufficient to in-
hibit tumor metastasis in the patient and in PDX models
derived from the patient’s tumor. However, p53 loss
augmented metastatic potential by enhancing prolifera-
tion and reducing apoptosis and this, in turn, led to
enhanced tumor growth. Thus, one contribution made
by p53 loss to late-stage tumor progression was to
promote tumor growth.
Previous studies conducted in vitro demonstrated that
p53 inhibits pathways that promote tumor escape from
the primary site, including ECM remodeling, connective
tissue degradation, cell adhesion and EMT [3, 4]. Indeed,
differential gene expression analysis revealed that these
pathways were also deregulated upon p53 silencing in
BC3 cells (Table S2 in Additional file 7). Despite these
expression changes, p53 silencing in BC3 tumor cells
did not significantly increase the shedding of CTCs into
the bloodstream of tumor-bearing mice. However, based
on the methods employed to detect CTCs, we cannot
rule out the possibility that silencing of p53 increased
CTC aggregation, thus improving their ability to seed
secondary sites [41]. However, it seems more likely that
CTC shedding was not affected by p53 status because
the tumor line already possessed the pathway changes
required for tumor escape.
p53 silencing resulted in the deregulation of many
genes that likely contributed to enhanced tumor growth.
It should be noted that in our study, gene expression
changes resulting from p53 loss were identified by ana-
lyzing human breast tumor cells grown in the mammary
fat pads of recipient mice. Mice were not exposed to
DNA-damaging agents, although tumor cells are known
to have intrinsic DNA damage. Troester et al. (2006)
silenced p53 in established breast cancer cell lines and
performed gene expression profiling on parental and
p53-deficient cells both in the absence and presence of
DNA damage [34]. Four of the differentially expressed
genes identified in the absence of exogenous DNA
damage in their study were also present on our list.
These included BTG2, inositol polyphosphate-5-
phosphatase (INPP5D), lysyl oxidase (LOX), and p21
protein (Cdc42/Rac)-activated kinase 6 (PAK6) (Table S1
in Additional file 6). In contrast to this in vitro analysis
on nontransformed basal-like cell lines, our gene expres-
sion analyses were derived from PDX tumors that were
engrafted in vivo. Thus, our analyses identified many
alterations not observed in other studies. Importantly,
BTG2 has been identified on both platforms, suggesting
that it is a critical regulator of p53 function.
BTG2 is a direct transcriptional target of p53 [38–40]
that regulates various cellular processes, including prolif-
eration, differentiation, and apoptosis [38, 42, 43]. BTG2
expression is deregulated in various cancers, consistent
with its role as a tumor suppressor protein. We observed
reduced expression of BTG2 upon p53 silencing, and
restoration of BTG2 expression in p53-deficient cells
reduced proliferation in vitro and reduced breast tumor
growth at both primary and secondary sites in vivo. In
addition, reduced BTG2 expression correlated with re-
duced overall survival as well as metastasis-free survival
of breast cancer patients, consistent with previous
reports [42, 44–46]. Herein, we extended these findings
by demonstrating that reduced BTG2 expression was
associated with reduced overall survival in patients with
TNBC. Thus, BTG2 functions as an important down-
stream effector of p53 to negatively regulate tumor
progression and is a candidate prognostic biomarker for
TNBC. Future experiments to examine the effect of
BTG2 expression in additional PDX models will deter-
mine if BTG2 inhibits metastasis in multiple genetic
backgrounds.
Although PDX models can largely recapitulate the
heterogeneity of human tumors [47], it is generally ac-
knowledged that they do not faithfully replicate human
tumor - human stromal interactions. This is because
human stroma is replaced by mouse stroma as a func-
tion of time after engraftment. In addition, PDX models
generated in immune-compromised mice do not ac-
count for the important contributions made by immune
cells to malignant progression. The immune system may
limit or promote metastasis, and it is possible that WT
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or mutant p53 controls metastasis by signaling through
immune components. Therefore, a thorough examination
of the function of p53 in an immune-competent model is
also warranted. Interestingly, Ding et al. (2010) reported
that PDX models established from a TNBC of the basal
subtype were more representative of the patient’s metasta-
sis than her primary breast tumor [48]. Thus, data identi-
fying these similarities between the metastasis and the
xenograft validate the PDX model as a useful system for
studying metastasis. Herein we report that human breast
tumors were capable of completing all stages of the
metastatic cascade in mice and metastatic lesions were
observed in organs normally found in patients with meta-
static breast cancer including lung, liver, bone, and brain.
Thus, PDX models may provide a powerful system for
delineating how heterogeneity contributes to metastatic
progression and for identifying metastatic drivers that can
then be functionally validated.
Conclusions
A paired PDX set of tumors differing only in p53 status
were used to study TNBC metastasis to lung, liver, bone,
brain, and lymph nodes in vivo. These models were used
to determine if p53 loss affects the metastatic potential
of an already fully metastatic tumor. We demonstrated
that p53 loss enhanced late-stage tumor progression by
increasing proliferation and reducing apoptosis and this,
in turn, led to enhanced tumor growth and cell shed-
ding. Loss of BTG2, a p53 effector protein, contributed
to the enhanced tumor growth and was associated with
reduced overall survival in patients with TNBC. Thus,
BTG2 is a candidate prognostic biomarker for TNBC.
Additional files
Additional file 1: Table S3. Mini-signature of genes that interact with
the p53 pathway and associated p values. (PDF 62 kb)
Additional file 2: Figure S1. Silencing of p53 increased cell proliferation
in vitro. BC3-p53WT and BC3-p53KD cells were plated on adherent cell
culture plates. (A) Total photon flux from cultured cells was quantified in
the presence of D-luciferin on an IVIS 100 immediately post-seeding. The
specific bioluminescence of BC3-p53WT cells was brighter than that of
BC3-p53KD cells; however, this difference did not adversely bias downstream
analyses because BC3-p53KD cells grew and metastasized faster than
BC3-p53WT, and any bias due to increased photon flux would be in favor of
Fig. 5 BTG2 is a clinically relevant modulator of tumor progression.
Kaplan-Meier curves were generated to assess correlations between
B cell translocation gene 2 (BTG2) expression and patient survival.
Top and bottom 25 % of patients were used as cutoffs for grouping.
a Low BTG2 expression correlates with decreased overall survival of
breast cancer patients (all subtypes). b Low BTG2 expression correlates
with decreased metastasis-free survival of breast cancer patients (all
subtypes). c Low BTG2 expression correlates with decreased overall
survival of triple-negative breast cancer (TNBC) patients. Number of
patients and p values are indicated in each panel
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BC3-p53WT. Total photon flux was normalized to cell number. p = 0.002,
t test. (B and C) BC3-p53WT and BC3-p53KD cells were plated on adherent
cell culture plates, and growth was quantified by MTT assays (B) or cell
proliferation assays (C). (D) Morphology of adherent BC3-p53WT and BC3-
p53KD cells growing as two-dimensional cultures was captured by bright
field microscopy. Magnified images are shown to the right of each image.
All error bars represent standard deviation from the mean (SD). (PDF 977 kb)
Additional file 3: Figure S2. p53 silencing does not increase number
of tumor-initiating cells. (A and B) Limiting numbers of BC3-p53WT or
BC3-p53KD were implanted to mouse mammary fat pads, and tumor
presence and growth was assessed with BLI. Limiting dilution transplantation
assays in immune-compromised mice demonstrated that as few as 10 BC3-
p53WT and BC3-p53KD cells were capable of initiating tumors (A) that grew
(exhibited increasing photon flux emission) over time (B). The presence of
co-implanted fibroblasts did not alter the tumor-initiating capacity of limiting
cell numbers. Error bars represent standard error of the mean (SEM). (C) One
million BC3-p53WT and BC3-p53KD cells were implanted into mouse
mammary fat pads, harvested at 0.5 cm diameter, and digested to single
cells that were plated on low-attachment plates in the absence of serum as
three-dimensional mammospheres. The number of established (primary)
mammospheres is shown. p = 1.0. (D) Primary mammospheres from (C)
were dissociated to single cells and replated on low attachment plates in
the absence of serum. The number of established (secondary) mammo-
spheres is shown. p = 0.06. Error bars represent standard deviation from the
mean (SD). (E) One million BC3-p53WT or BC3-p53KD cells were implanted
into mouse mammary fat pads and harvested when they reached 0.5 cm
diameter. Tumors were digested to single cells and stained with antibodies
for flow cytometry to assess expression of CD24 and CD44. The percentage
of cells from BC3-p53WT and BC3-p53KD mammary tumors that exhibit
high levels of CD44 and low levels of CD24 is shown. p = 0.06. Error bars
represent standard deviation from the mean (SD) (C-E). Wilcoxon rank sum
tests were used for statistical analyses. (PDF 134 kb)
Additional file 4: Figure S3. p53 silencing increases growth at metastatic
sites. BC3-p53WT or BC3-p53KD cells were injected to the left cardiac ventricle
(A, p = 0.22 at 4 weeks; p = 0.01 at 6 weeks)) or tail vein (B, p = 0.03 at
13 weeks), and mice were subjected to BLI in vivo at the indicated time
points. Total photon flux was assessed on an IVIS SPECTRUM and quantified.
Each data point represents one mouse. All error bars represent standard error
of the mean (SEM). Wilcoxon rank sum tests were used for statistical analyses.
(PDF 73 kb)
Additional file 5: Figure S4. CTC number correlates with mammary
tumor size. Mouse mammary fat pads were engrafted with BC3-p53WT or
BC3-p53KD. Whole blood was extracted from mice in a terminal blood
draw by cardiac puncture. Red blood cells were lysed, and circulating
tumor cells (CTCs) were assessed by flow cytometry for mCherry-positive
cells. BLI was performed on mammary tumors and lungs at necropsy.
(A and B) CTCs were quantified by flow cytometry and normalized to
total photon flux (A) or volume (B) of each corresponding mammary
tumor at indicated time points. Error bars represent standard error of the
mean (SEM). (C) CTC number was plotted versus photon flux of the
mammary tumor within each mouse. Pearson correlation = 0.82, p <0.001.
(D) CTC number was plotted versus tumor volume within each mouse.
Pearson correlation = 0.61, p = 0.001. (E) CTC number was plotted versus
photon flux in the lung. Pearson correlation = 0.79, p <0.001. (F) CTC
number was plotted versus time of lymph node metastasis detection.
Pearson correlation = 0.36, p = 0.23. Each data point represents one
mouse. (PDF 2462 kb)
Additional file 6: Table S1. RNA-Seq signature of genes that are
deregulated upon p53 loss in BC3 mammary tumors. (PDF 123 kb)
Additional file 7: Table S2. Pathway analysis of RNA-Seq expression
signature consisting of genes deregulated upon p53 knockdown. (PDF 63 kb)
Additional file 8: Figure S5. Ectopic expression of BTG2 in BC3-p53KD
cells reduces cell proliferation in vitro. BC3-p53KD cells were stably
transduced with plasmids encoding BTG2 or GFP (control). mRNA (A)
and protein (B) levels of BTG2 were determined by qRT-PCR and
Western blotting. Cell proliferation was assessed in vitro using cell
proliferation assays (C) or MTT assays (D and E). Error bars represent
standard deviation from the mean (SD). (PDF 1964 kb)
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